<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564031</url>
  </required_header>
  <id_info>
    <org_study_id>166/99</org_study_id>
    <secondary_id>166/99</secondary_id>
    <nct_id>NCT00564031</nct_id>
  </id_info>
  <brief_title>Hormonal Replacement Therapy and Small Artery Function</brief_title>
  <acronym>HRT</acronym>
  <official_title>Hormonal Replacement Therapy and Small Artery Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endothelial dysfunction in resistance arteries in women after the menopause is important for&#xD;
      the development of high blood pressure and cardiovascular disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We aim to study the effects of different hormone replacement therapies (HRT) on the function&#xD;
      and morphology of resistance arteries, and to look for their mechanistic basis. We expect&#xD;
      that HRT with estrogens or in combination with MPA may benefit the function of resistance&#xD;
      arteries and may preserve the morphological integrity of endothelial cells by regulatory&#xD;
      actions on the cytoskeleton.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endothelium-dependent dilatation</measure>
    <time_frame>3 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pressure-induced tone and vascular morphology</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Femanest</intervention_name>
    <description>2mg/day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gestapuran</intervention_name>
    <description>5mg/day</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Femanest plus Gestapuran</intervention_name>
    <description>combined daily</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All women had been amenorrheic for at least 1.5 year.&#xD;
&#xD;
          -  Menopausal status was confirmed by a serum concentration of follicular- stimulating&#xD;
             hormone (FSH &gt; 34 IU/ml) and estradiol (E2 &lt;50 pmol/l).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cigarette smokers and women with:&#xD;
&#xD;
               -  Hypertension&#xD;
&#xD;
               -  Diabetes mellitus&#xD;
&#xD;
               -  Clinical manifestations of arteriosclerosis (coronary heart disease, peripheral&#xD;
                  artery disease, or cerebrovascular disease)&#xD;
&#xD;
               -  Venous thromboembolic disease&#xD;
&#xD;
               -  Liver disorders&#xD;
&#xD;
               -  Unexplained vaginal bleeding; and&#xD;
&#xD;
               -  Personal or family history of breast cancer were excluded.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karolina Kublickiene, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska University hospital-huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>November 26, 2007</study_first_submitted>
  <study_first_submitted_qc>November 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2007</study_first_posted>
  <last_update_submitted>November 26, 2007</last_update_submitted>
  <last_update_submitted_qc>November 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2007</last_update_posted>
  <keyword>hormone replacement therapy; endothelial function;</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

